We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

GE Forms CAD Partnership with Deus Technologies

By HospiMedica staff writers
Posted on 09 Dec 2002
Print article
A strategic partnership to develop a new digital computer-aided detection (CAD) product for lung cancer has been announced by GE Medical Systems (Waukesha, WI, USA) and Deus Technologies, LLC (Rockville, MD, USA). As part of the agreement, GE will have exclusive distribution rights to the new CAD product, which will be used on GE's suite of digital radiography x-ray systems.

Currently, the only CAD product for early lung cancer detection is the RapidScreen RS-2000 of Deus, for use with analog x-ray systems. This system identifies regions of interest on chest images that may have features associated with solitary pulmonary nodules, an important indication for early-stage lung cancer. According to the American Cancer Society, only 15% of lung cancer is detected in stage 1A, the most treatable stage. With the development of a new digital product, the two companies believe that CAD capabilities will be better integrated into a doctor's workflow.

"We are excited to work with GE Medical Systems on this initiative,” explained Michael Yeh, Ph.D., CEO of Deus. "Technical advances like this are particularly important when you consider that more than 50% of all radiologic procedures performed in the United States are chest x-rays.”


Related Links:
GE Medical
Deus Technologies
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Endoscopic Suturing System
OverStitch
New
Antimicrobial Barrier Dressing
ACTICOAT FLEX

Print article

Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more